1. Home
  2. OLED vs CPRX Comparison

OLED vs CPRX Comparison

Compare OLED & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Display Corporation

OLED

Universal Display Corporation

HOLD

Current Price

$78.06

Market Cap

3.7B

Sector

Technology

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.45

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLED
CPRX
Founded
1985
2002
Country
United States
United States
Employees
469
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.9B
IPO Year
1996
2006

Fundamental Metrics

Financial Performance
Metric
OLED
CPRX
Price
$78.06
$31.45
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$125.00
$35.00
AVG Volume (30 Days)
713.3K
1.8M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
2.23%
N/A
EPS Growth
9.25
28.24
EPS
0.76
0.50
Revenue
$650,611,000.00
$119,072,803.00
Revenue This Year
$5.88
$9.20
Revenue Next Year
$10.36
$10.51
P/E Ratio
$103.61
$62.94
Revenue Growth
0.45
16.39
52 Week Low
$77.15
$19.05
52 Week High
$161.92
$32.56

Technical Indicators

Market Signals
Indicator
OLED
CPRX
Relative Strength Index (RSI) 34.00 70.75
Support Level N/A $31.25
Resistance Level $96.40 $32.56
Average True Range (ATR) 4.02 0.04
MACD -0.70 -0.08
Stochastic Oscillator 9.14 75.00

Price Performance

Historical Comparison
OLED
CPRX

About OLED Universal Display Corporation

Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: